Differential effect of carbamazepine and oxcarbazepine on excitatory synaptic transmission in rat hippocampus

Synapse

Volumn 62, Issue 10, 2008, Pages 783-789

  Giustizieri, Michela ^a   Armogida, Marta ^a   Berretta, Nicola ^a   Federici, Mauro ^a   Piccirilli, Silvia ^b   Mercuri, Nicola B ^a,c   Nistico, Robert ^a,d  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d UNIVERSITY OF CALABRIA   (Italy)

Author keywords

Antiepileptic drugs; Glutamate receptors; Hippocampus; Patch clamp recordings; Sodium channels

Indexed keywords

CARBAMAZEPINE; IONOTROPIC RECEPTOR; KAINIC ACID; MAPATUMUMAB; N METHYL DEXTRO ASPARTIC ACID; OXCARBAZEPINE;

ACTION POTENTIAL; ADDITION REACTION; ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; CONCENTRATION RESPONSE; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; ELECTRIC CURRENT; ELECTROPHYSIOLOGY; EVOKED RESPONSE; HIPPOCAMPUS; IC 50; MEMORY DISORDER; NONHUMAN; POSTSYNAPTIC POTENTIAL; PRESYNAPTIC POTENTIAL; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; RAT; RECEPTOR DOWN REGULATION; SYNAPTIC TRANSMISSION; WISTAR RAT;

ANIMALS; CARBAMAZEPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY POSTSYNAPTIC POTENTIALS; HIPPOCAMPUS; RATS; RATS, WISTAR; SYNAPTIC TRANSMISSION;

EID: 50249154867     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20556     Document Type: Article

References (40)

1. Ambrósio AF, Silva AP, Malva JO, Soares-da-Silva P, Carvalho AP, Carvalho CM. 1999. Carbamazepine inhibits L-type Ca2+ channels in cultured rat hippocampal neurons stimulated with glutamate receptor agonists. Neuropharmacology 38:1349-1359.
2. Anderson WW, Collingridge GL. 2007. Capabilities of the WinLTP data acquisition program extending beyond basic LTP experimental functions. J Neurosci Methods 162:346-356.
3. Benes J, Parada A, Figueiredo AA, Alves PC, Freitas AP, Learmonth DA, Cunha RA, Garrett J, Soares-da-Silva P. 1999. Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5- carboxamide derivatives. J Med Chem 152582-2587.
4. Brunbech L, Sabers A. 2002. Effect of antiepileptic drugs on cognitive function in individuals with epilepsy: A comparative review of newer versus older agents. Drugs 62:593-604.
5. Cai Z, McCaslin PP. 1992. Amitriptyline, desipramine, cyproheptadine and carbamazepine, in concentrations used therapeutically, reduce kainate- and N-methyl-D-aspartate-induced intracellular Ca2+ levels in neuronal culture. Eur J Pharmacol 219:53-57.
6. Calabresi P, De Murtas M, Stefani A, Pisani A, Sancesario G, Mercuri NB, Bernardi G. 1995. Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. I. Modulation of corticostriatal synaptic transmission. Epilepsia 10:990-996.
7. Calabresi P, Siniscalchi A, Pisani A, Stefani A, Mercuri NB, Bernardi G. 1996. A field potential analysis on the effects of lamotrigine. GP 47779, and felbamate in neocortical slices. Neurology 47:557-562.
8. Cunha RA, Coelho JE, Costenla AR, Lopes LV, Parada A, de Mendonça A, Sebastião AM, Ribeiro JA. 2002. Effects of carbamazepine and novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives on synaptic transmission in rat hippocampal slices. Pharmacol Toxicol 90:208-213.
9. Dam M. 1994. Practical aspects of oxcarbazepine treatment. Epilepsia 35:S23-S25.
10. Dürmüller N, Craggs M, Meldrum BS. 1994. The effect of the non-NMDA receptor antagonists GYKI 52466 and NBQX and the competitive NMDA receptor antagonist D-CPPene on the development of amygdala kindling and on amygdala-kindled seizures. Epilepsy Res 17:167-174.
11. Elting JW, Suiter GA, Kaste M, Lees KR, Diener HC, Hommel M, Versavel M, Teelken AW, De Keyser J. 2002. AMPA antagonist ZK200775 in patients with acute ischemic stroke: Possible glial cell toxicity detected by monitoring of S-100B serum levels. Stroke 33:2813-2818.
12. Filliat P, Pernot-Marino I, Baubichon D, Lallement G. 1998. Behavioral effects of NBQX, a competitive antagonist of the AMPA receptors. Pharmacol Biochem Behav 59:1087-1092.
13. Friis ML, Kristensen O, Boas J, Dalby M, Deth SH, Gram L, Mikkelsen M, Pedersen B, Sabers A, Worm-Petersen J, Andersen D, Jensen PK. 1993. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand 87:224-227.
14. Gates JR. 2000. Side effect profiles and behavioral consequences of antiepileptic medications. Epilepsy Behav 1:153-159.
15. Harden CL. 1994. New antiepileptic drugs. Neurology 44:787-795.
16. Jakus R, Graf M, Ando RD, Balogh B, Gacsalyi I, Levay G, Kantor S, Bagdy G. 2004. Effect of two noncompetitive AMPA receptor antagonists GYKI 52466 and GYKI 53405 on vigilance, behavior and spike-wave discharges in a genetic rat model of absence epilepsy. Brain Res 1008:236-244.
17. Karceski S, Morrell MJ, Carpenter D. 2005. Treatment of epilepsy in adults: Expert opinion, 2005. Epilepsy Behav 7(Suppl 1):S1-S64.
18. Kemp JA, McKernan RM. 2002. NMDA receptor pathways as drug targets. Nat Neurosci 5(Suppl):1039-1042.
19. Lampe H, Bigalke H. 1990. Carbamazepine blocks NMDA-activated currents in cultured spinal cord neurons. Neuroreport 1:26-28.
20. Macdonald RL. 1996. Is there a mechanistic basis for rational polypharmacy? Epilepsy Res Suppl 11:79-93.
21. Macdonald RL, Kelly KM. 1994. Mechanisms of action of currently prescribed and newly developed antiepileptic drugs. Epilepsia 35:S41-S50.
22. McLean M. 2002. Oxcarbazepine: Mechanism of action. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, editors. Antiepileptic drugs, 5th ed. Philadelphia: Lippincott, Williams & Wilkins. pp 451-458.
23. Meador KJ, Loring DW, Ray PG, Murro AM, King DW, Nichols ME, Deer EM, Goff WT. 1999. Differential cognitive effects of carbamazepine and gabapentin. Epilepsia 40:1279-1285.
24. Meldrum BS. 1994. The role of glutamate in epilepsy and other CNS disorders. Neurology 44:S14-S23.
25. Meldrum BS, Rogawski MA. 2007. Molecular targets for antiepileptic drug development. Neurotherapeutics 4:18-61.
26. Ortinski P, Meador KJ. 2004. Cognitive side effects of antiepileptic drugs. Epilepsy Behav 5:S60-S65.
27. Phillips I, Martin KF, Thompson KS, Heal DJ. 1997. Weak blockade of AMPA receptor-mediated depolarisations in the rat cortical wedge by phenytoin but not lamotrigine or carbamazepine. Eur J Pharmacol 337:189-195.
28. Potschka H, Löscher W, Wlaź P, Behl B, Hofmann HP, Treiber HJ, Szabo L. 1998. LU 73068, a new non-NMDA and glycine/NMDA receptor antagonist: Pharmacological characterization and comparison with NBQX and L-701324 in the kindling model of epilepsy. Br J Pharmacol 125:1258-1266.
29. Prevey ML, Delaney RC, Cramer JA, Mattson RH. 1998. Complex partial and secondarily generalized seizure patients: Cognitive functioning prior to treatment with antiepileptic medication. VA Epilepsy Cooperative Study 264 Group. Epilepsy Res 30:1-9.
30. Rogawski MA, Porter RJ. 1990. Antiepileptic drugs: Pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev 42:223-286.
31. Schmidt D. 2002. The clinical impact of new antiepileptic drugs after a decade of use in epilepsy. Epilepsy Res 50:21-32.
32. Schmidt D, Kramer G. 1994. The new anticonvulsant drugs. Implications for avoidance of adverse effects. Drug Saf 11:422-431.
33. Sitges M, Chiu LM, Guarneros A, Nekrassov V. 2007a. Effects of carbamazepine, phenytoin, lamotrigine, oxcarbazepine, topiramate and vinpocetine on Na+ channel-mediated release of [3H]glutamate in hippocampal nerve endings. Neuropharmacology 52:598-605.
34. Sitges M, Guarneros A, Nekrassov V 2007b. Effects of carbamazepine, phenytoin, valproic acid, oxcarbazepine, lamotrigine, topiramate and vinpocetine on the presynaptic Ca2+ channel-mediated release of [3H]glutamate: Comparison with the Na+ channel-mediated release. Neuropharmacology 53:854-862.
35. Stefani A, Pisani A, De Murtas M, Mercuri NB, Marciani MG, Calabresi P. 1995. Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. II. Modulation of high-voltage-activated calcium currents. Epilepsia 36:997-1002.
36. Suzuki F, Heinrich C, Boehrer A, Mitsuya K, Kurokawa K, Matsuda M, Depaulis A. 2005. Glutamate receptor antagonists and benzodiazepine inhibit the progression of granule cell dispersion in a mouse model of mesial temporal lobe epilepsy. Epilepsia 46:193-202.
37. Upton N. 1994. Mechanisms of action of new antiepileptic drugs: Rational design and serendipitous findings. Trends Pharmacol Sci 15:456-463.
38. Vermeulen J, Aldenkamp AP. 1995. Cognitive side-effects of chronic antiepileptic drug treatment: A review of 25 years of research. Epilepsy Res 22:65-95.
39. Walker MC, Sander JW. 1994. Developments in antiepileptic drug therapy. Curr Opin Neurol 7:131-139.
40. Willow M, Gonoi T, Catterall WA. 1985. Voltage clamp analysis of the inhibitory actions of diphenylhydantoin and carbamazepine on voltage-sensitive sodium channels in neuroblastoma cells. Mol Pharmacol 27:549-558.